[Comment] Could enpatoran add to our therapeutic toolbox in SLE?
Systemic lupus erythematosus (SLE) is a clinically and serologically heterogeneous condition in which therapeutic advances have been slower than for other rheumatic diseases. Only two new therapies have been licensed for use since the 1950s.1,2 These target B-cell activating factor (BAFF)1 and type-
ORIGINAL SOURCE →via The Lancet
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · conflict
- [CONFLICT] Intermodal Asia
- [CONFLICT] UNDRR Regional Office for Arab States
- [CONFLICT] Digital security in war and conflict: challenges for civil society and tools for resilience
- [CONFLICT] Securing the Untrusted Agentic Development Layer
- [CONFLICT] [World Report] Lebanon's health system: a silent casualty of war
- [CONFLICT] [World Report] “We don’t want it to happen to others”: suicide in young Māori